News Aktuell

CROMA-PHARMA GmbH

12.06.2023 - 15:25

Croma-Pharma announces enrollment of first patient in hyaluronic acid dermal filler clinical trial in China

Vienna (ots/PRNewswire) - Croma-Pharma® ('Croma') announced today that in June the first patient will be enrolled in the clinical trial1 for the approval of its hyaluronic acid dermal filler Princess® Volume Plus Lidocaine2 in China. The ...To the press release of CROMA-PHARMA GmbH

01.06.2023 - 11:00

Croma-Pharma: Launch of topical anaesthetic Pliaglis® in Europe

Vienna (ots/PRNewswire) - Croma-Pharma, a global player and challenger in the dynamically growing, minimally invasive aesthetics market, announces that it will launch Pliaglis®, a topical local anaesthetic for superficial dermatological procedures, ...To the press release of CROMA-PHARMA GmbH

11.05.2023 - 11:01

Croma-Pharma receives marketing authorisation for Letybo® in a further 12 European markets

Vienna (ots/PRNewswire) - Croma (Croma-Pharma® GmbH) announced today that it has received marketing authorisation for Letybo®, the company's botulinum toxin product, in 12 additional European markets. These include Belgium, Cyprus, Czech Republic, ...To the press release of CROMA-PHARMA GmbH

09.05.2023 - 18:38

/C O R R E C T I O N -- Croma-Pharma/

Vienna (ots/PRNewswire) - In the news release, Croma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter, issued 09-May-2023 by Croma-Pharma over PR Newswire, we are advised by the company that the ...To the press release of CROMA-PHARMA GmbH

09.05.2023 - 14:21

Croma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter

Vienna (ots/PRNewswire) - - Company reports strong financial results for 2022 with 27% revenue growth in 2022 and significantly increased margins - Growth driven by launch of Letybo® and its catalytic effect on the existing portfolio as well as ...To the press release of CROMA-PHARMA GmbH